Interleukin 37

Source: Wikipedia, the free encyclopedia.
(Redirected from
IL1F7
)
IL37
Identifiers
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_014439
NM_173202
NM_173203
NM_173204
NM_173205

n/a

RefSeq (protein)

NP_055254
NP_775294
NP_775295
NP_775296
NP_775297

n/a

Location (UCSC)Chr 2: 112.91 – 112.92 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Interleukin 37 (IL-37), also known as

tumor cell growth.[3]

Gene location and structure

The IL-37

homolog gene in mice genome.[4] IL-37 undergoes alternative splicing with 5 different splice variants depending on which of the 6 possible exons are being expressed: IL-37a-e.[5] IL-37b is the largest and most studied one; it shares the beta barrel structure that is spread within the interleukin-1 family.[3]

Gene expression

IL-37a,b,c are being

epithelial cells
.

Some IL-37 isoforms are tissue specific and have varying lengths depending on which exons are being expressed:

IL-37a is found in the brain. The isoform includes exons 3, 4, 5, and 6 and the isoform is 192 amino acids in length

IL-37b is found in the

urogenital tract
. Exons 1, 2, 4, 5, and 6 are expressed and the isoform is 218 amino acids in length.

IL-37c is found in the heart, and contains exons 1, 2, 5, and 6 for a total amino acid length of 197.

IL-37d is found in the bone marrow and includes exons 1, 4, 5, and 6 for a total length of 197.

IL-37e is found in the testis and includes exons 1, 5, and 6 totaling 157 amino acids.[3][6]

Function

The mechanism of IL-37 functions is still to be elucidated. Known functions of IL-37 include

extracellulary, classifying the cytokine as dual-function.[3]

IL-37 synthesis

IL-37, similar to other members of the interleukin-1 family, is synthesized by blood monocytes in a precursor form and secreted into the cytoplasm in response to inflammatory signaling. Examples of relevant inflammatory signals include TLR agonists, IL-1β, or TGF-β.[5] Full maturation requires cleavage by Caspase-1.[7]

Immune system inhibition

IL-37 is known to have immunosuppression properties through two different binding mechanisms:

Interaction with IL-18 cell surface receptors - Intracellular IL-37 can be released from cells following necrosis or apoptosis.[6] IL-37 has two similar amino acid residues with IL-18, and thus extracellular IL-37 can interact with IL-18 receptor (IL-18R) and co-receptor IL-1 receptor 8 (IL-1R8). The affinity of IL-37b to IL-18R alpha subunit is much lower compared to IL-18. IL-37b interacts with IL-18 binding protein (IL-18BP), that is an antagonist of IL-18. The binding of IL-37b enhances the IL-18BP functions and can upregulate anti-inflammatory signals.[4][7]

Binding to SMAD3 receptor - Mature intracellular IL-37 can form functional complexes with

TNF-α.[5][8][6]

Tumor-controlled expression

IL-37 functions are active at low IL-37 concentrations. Higher concentrations leads to inactivation via dimer formation.

Colon cancer, lung cancer, Multiple Myeloma, and Hepatoma Carcinoma were correlated with decreased expression of IL-37 expression in affected areas.[5]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000125571Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^
    PMID 29552110
    .
  4. ^ .
  5. ^ .
  6. ^ .
  7. ^ .
  8. .

Further reading

External links

This page is based on the copyrighted Wikipedia article: IL1F7. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy